Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-11-01
2005-11-01
Weber, Jon (Department: 1653)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S007100, C424S484000, C424S279100, C530S300000, C530S350000, C530S380000, C514S002600, C514S012200, C514S056000
Reexamination Certificate
active
06960452
ABSTRACT:
Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin-binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would?? Healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.
REFERENCES:
patent: 4613665 (1986-09-01), Larm
patent: 4810784 (1989-03-01), Larm
patent: 5100668 (1992-03-01), Edelman et al.
patent: 5171670 (1992-12-01), Kronenberg et al.
patent: 5202247 (1993-04-01), Kilburn et al.
patent: 5504001 (1996-04-01), Foster
patent: 5561982 (1996-10-01), Tunkel et al.
patent: 5693341 (1997-12-01), Schroeder et al.
patent: 5773577 (1998-06-01), Capello
patent: 5840837 (1998-11-01), Krstenansky et al.
patent: 5877153 (1999-03-01), Harris et al.
patent: 2002/0146414 (2002-10-01), Sakiyama-Elbert et al.
patent: 2003/0119186 (2003-06-01), Hubbell et al.
patent: WO 92/02620 (1992-02-01), None
Mosher et al. , J. Biol. Chem. 255, 1181-1188 (1980).
Besson, et al., “Synthetic peptide substrates for a conductimetric assay ofPseudomonas aeruginosaelastase,”Analytical Biochemistry237(0232):216-223 (1996).
Borrajo, et al., “Derivatized Cyclodextrins as peptidometics: Influence on Neurite Growth,”Bioorganic and Medicinal Chemistry Letters 7:1185-90 (1997).
Coombs, et al. “Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator,”J. Biol. Chem.273(8):4323-8 (1998).
Dimilla, et al., “Mathematical model for the effects of adhesion and mechanics on cell migration speed,”Biophys. J.60(1):15-37 (1991).
Dinbergs, et al., “Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions,”J. Biol. Chem.271(47):29822-9 (1996).
Edelman, et al., “Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries,”J. Clin. Invest.89(2):465-73 (1992).
Edelman, et al., “Controlled and modulated release of basic fibroblast growth factor,”Biomaterials.12(7):619-26 (1991).
Edelman, et al., “Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition,”Proc. Natl. Acad. Sci. U. S. A.90(4):1513-7 (1993).
Edgar, et al., “The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival,”Embo J.3(7):1463-8 (1984).
Götz, et al., “Neurotrophin-6 is a new member of the nerve growth factor family,”Nature372(6503):266-9 (1994).
Harada, et al., “Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts,”J. Clin. Invest.94(2):623-30 (1994).
Kallapur, et al, “The neural cell adhesion molecule (NCAM) heparin binding domain binds to cell surface heparan sulfate proteoglycans,”J. Neurosci. Res.33(4):538-48 (1992).
Kaneda, et al., “Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro,”J. Biochem.119(6):1150-6 (1996).
Kleinman, et al., “The laminins: a family of basement membrane glycoproteins important in cell differentiation and tumor metastases,”Vitam. Horm.47:161-86 (1993).
Hata, et al., “Binding of lipoprotein lipase to heparin. Identification of five critical residues in two distinct segments of the amino-terminal domain,”J. Biol. Chem.268(12):8447-57 (1993).
Haugen, et al, “Central and peripheral neurite outgrowth differs in preference for heparin-binding versus integrin-binding sequences,”J. Neurosci.12(6):2034-42 (1992).
Herbert, et al., “Effects of fibinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels,”J. Comp. Neurol.365(3):380-91 (1996).
Herbert, et al., “Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels,”J. Biomed. Mater. Res.40(4):551-9 (1998).
Kallapur, et al, “The neural cell adhesion molecule (NCAM) heparin binding domain binds to cell surface heparan sulfate proteoglycans,”J. Neurosci. Res.33(4):538-48 (1992).
Kaneda, et al., “Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro,”J. Biochem.119(6):1150-6 (1996).
Kiguchi, et al., “Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol,”Mol. Carcinog.22(2):73-83 (1998).
Kinosaki, et al., “Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF),”Biochim. Biophys. Acta.1384(1):93-102 (1998).
Lopez, et al., “Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters,”J. Pharmacol. Exp. Ther.282(1):385-90 (1997).
Lopez, et al., “Local perivascular administration of basic fibroblast growth factor: drug delivery and toxicological evaluation,”Drug Metab. Dispos.24(8):922-4 (1996).
Martin & Timpl, “Laminin and other basement membrane components,”Annu. Rev. Cell. Biol.3:57-85 (1987).
Massia, et al., “An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3-mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation,”J. Cell. Biol.114(5):1089-100 (1991).
McCaffrey, et al., “Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1,”J. Cell. Physiol.152(2):430-40 (1992).
Netzel-Arnett, et al., “Sequence specificities of human fibroblast and neutrophil collagenases,”J. Biol. Chem.266(11):6747-55 (1991).
Nolo, et al., “Developmentally regulated neurite outgrowth response from dorsal root ganglion neurons to heparin-binding growth-associated molecule (HB-GAM) and the expression of HB-GAM in the targets of the developing dorsal root ganglion neurites,”Eur. J. Neurosci.8(8):1658-65 (1996).
Presta, et al., “Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region,”Biochem. Biophys. Res. Commun.185(3):1098-107 (1992).
Rogers, et al., “Neuron-specific interactions with two neurite-promoting fragments of fibronectin,”J. Neurosci.5(2):369-78 (1985).
Sellke, et al., “Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation,”Am. J. Physiol.267(4 Pt 2):H1303-11 (1994).
Smith, et al., “Rapid identification of highly active and selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries,”J. Biol. Chem.270(12):6440-9 (1995).
Spillman, et al., “Defining the interleu
Hubbell Jeffrey A.
Sakiyama Shelly E.
Schense Jason C.
Eidgenossische Technische Hochschule Zurich
Kam Chih-Min
Pabst Patent Group LLP
Universitat Zurich
Weber Jon
LandOfFree
Enzyme-mediated modification of fibrin for tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzyme-mediated modification of fibrin for tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme-mediated modification of fibrin for tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3515014